Drug intelligence / Profile preview

deacetoxycephalosporin C

Development stage: Unknown
Modality: Small Molecules

Overview

Deacetoxycephalosporin C is a small molecule antibiotic and an intermediate in the biosynthesis of cephalosporins. It is produced by certain fungi and bacteria such as Cephalosporium (now Acremonium) and Streptomyces species. Functionally related to cephalosporin C, it serves as a precursor in the enzymatic conversion from penicillin N to cephalosporins via the action of deacetoxycephalosporin C synthase. While it exhibits some antibiotic activity itself, its primary significance lies in its role as a key intermediate for industrial production of semisynthetic cephalosporins[1][3][6]. It is not approved for clinical use in humans.

Other names: deacetoxycephalosporin Cdesacetoxycephalosporin CWS-3442AWS3442AWS 3442AAntibiotic WS-3442A7-ADCA Impurity 6

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on deacetoxycephalosporin C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deacetoxycephalosporin C.

Explore the full profile